Cabenuva is administered monthly as an injectable. This can replace HIV patients’ current antiretroviral regimen, which requires them to take multiple pills several times a day, cautiously scheduled around meals.
“This approval will allow some patients the option of receiving once-monthly injections in lieu of a daily oral treatment regimen,” John Farley MD, the director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research, said in a news release. “Having this treatment available for some patients provides an alternative for managing this chronic condition.”
The approval was granted to ViiV Healthcare, a U.K.-based drugmaker with its U.S. headquarters in Research Triangle Park, N.C.
More articles on pharmacy:
Fauci: US rejoining WHO means it will join Covax
New Jersey governor blames CVS, Walgreens for slow vaccine rollout
California says halted Moderna vaccine batch is safe
